Welcome to our dedicated page for Oncotelic Therapeutics SEC filings (Ticker: OTLC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Oncotelic Therapeutics, Inc. (OTLC) SEC filings page on Stock Titan provides direct access to the company’s official regulatory disclosures, including Forms 10-K, 10-Q, S-1, S-1/A, 8-K, and related documents. As a clinical-stage biopharmaceutical company focused on oncology, immunotherapy, and rare pediatric indications, Oncotelic uses these filings to report on its financial condition, capital-raising activities, joint ventures, and material agreements.
Recent Form 8-K filings detail unregistered sales of equity securities through unit offerings of notes and warrants to accredited investors, including conversion features into Oncotelic common stock or shares of consolidated minority-owned subsidiary EdgePoint AI, Inc. They also describe amendments to independent contractor and restricted stock agreements tied to market capitalization milestones, as well as corporate presentations and press releases, such as the announcement of open access to the PDAOAI platform and its TGF-β literature corpus.
Registration statements on Form S-1 and Form S-1/A outline resale arrangements with Mast Hill Fund, LP under a Note Purchase Agreement and an Equity Purchase Agreement. These documents specify the number of shares registered, warrant coverage, and the company’s status as a smaller reporting company. Together with periodic reports, they give investors insight into equity structures, potential dilution, and ongoing financing strategies.
Additional filings, such as Form 12b-25 (NT 10-Q), explain timing extensions for quarterly reports and provide context on anticipated changes in results of operations. By reviewing these filings, users can understand how Oncotelic structures its financings, manages joint venture interests like GMP Bio and Sapu Nano, and discloses risks and forward-looking statements associated with its oncology, RNA therapeutic, nanomedicine, and AI-driven platforms. Stock Titan’s interface, combined with AI-powered summaries, helps interpret complex disclosures, highlight key terms in offerings and agreements, and surface material events that may be relevant to OTLC shareholders and analysts.
Oncotelic Therapeutics entered a Joint Development, Manufacturing, and Licensing Agreement with TechForce Robotics on March 31, 2026 to co-develop AI-enabled, GMP-compliant robotic systems for pharmaceutical manufacturing. The product integrates TechForce’s robotic hardware with Oncotelic’s proprietary PDAOAI platform.
All AI-related foreground intellectual property and data generated by the product will be owned exclusively by Oncotelic, while TechForce owns its standalone hardware innovations and jointly developed IP is jointly owned. Commercial revenue terms, including revenue sharing and royalties, will be set later in a separate Commercialization and Licensing Agreement, and neither party may begin revenue-generating activities without mutual written consent.
The agreement uses project-based funding with milestone payments, allows either party to terminate for convenience on 60 days’ notice, and restricts TechForce for 12 months after termination from licensing the jointly developed IP for pharma manufacturing without Oncotelic’s approval. Oncotelic issued a press release on April 2, 2026 announcing the strategic partnership.
Oncotelic Therapeutics, Inc. submitted a Form 12b-25 notifying the SEC that its annual report on Form 10-K for the period ended December 31, 2025 could not be filed on time because the company is still compiling the necessary financial information. The company states it expects to file within the permitted extension period.
Oncotelic Therapeutics, Inc. reported that its minority-owned company Sapu Nano will introduce its Deciparticle™ nanomedicine platform and present its clinical pipeline at BIO-Europe Spring 2026 on March 25, 2026. Sapu Nano has been selected as a Presenting Company at the conference.
The session will feature Deciparticle, a sub-20 nm drug delivery platform designed to optimize tissue distribution, improve pharmacokinetics, and reduce formulation-related toxicities for hydrophobic oncology drugs. Two lead candidates include an intravenous everolimus formulation in Phase 1 clinical trials and an advanced docetaxel formulation entering Phase 1.
The disclosure also reiterates Oncotelic’s broader oncology strategy, including rare pediatric cancer designations through its 45% joint venture GMP Bio and programs such as OT-101, CA4P, OXi 4503, and AL-101 for neurological and sexual health indications, while emphasizing extensive forward-looking statement cautions.
Oncotelic Therapeutics, Inc. filed a current report describing a scientific disclosure rather than a financial event. The company announced that Sapu Nano, an entity in which it holds a minority interest, will present new everolimus toxicology data at the 2026 Society of Toxicology Annual Meeting and ToxExpo in San Diego. The poster, titled “Everolimus Toxicology: Tissue Concentration Effects,” examines how tissue-level exposure to everolimus relates to organ-specific toxic outcomes, extending understanding beyond traditional plasma pharmacokinetics. The work supports development of intravenous and nanoparticle-based formulations designed to better control drug distribution. The presentation is scheduled for March 23, 2026, during the ADME/Toxicokinetics I poster session.
Oncotelic Therapeutics, Inc. entered a Securities Purchase Agreement with Mast Hill Fund, LP and issued a secured convertible promissory note with an aggregate gross principal amount of $398,333.33. The note carries a 10% original issue discount, 10% annual interest and matures around one year after the agreement date, subject to earlier prepayment or default.
The note is convertible into common stock at a fixed price of $0.07 per share, subject to adjustment, and is secured by most company and subsidiary assets, excluding assets tied to its Dragon Overseas Capital joint venture. The company also issued 1,422,613 warrants with a $0.15 exercise price. Proceeds must be used for general working capital under specific restrictions. A registration rights agreement was signed to register shares underlying the note and warrants, which were issued under a private placement exemption.
Oncotelic Therapeutics Chairman and CEO Vuong Trieu reported an award of 4,426 shares of Series A Convertible Preferred Stock on January 22, 2026. The preferred stock is convertible at the holder’s option into 4,426,000 shares of common stock on a one-for-one thousand basis and was issued at a stated price of $0.00 per share as compensation for achieving performance milestones under a Restricted Stock Agreement dated January 21, 2026. Following this grant, Dr. Trieu beneficially owns 8,491 shares of the Series A Convertible Preferred Stock directly.
Oncotelic Therapeutics approved a new milestone-based equity award for its CEO, Dr. Vuong Trieu, tied to improving the company’s capital structure. Under a restricted stock agreement, the company may issue up to 26,512 shares of Series A Preferred Stock, each convertible into 1,000 common shares, based on four specified financing and debt-related milestones. Dr. Trieu has already met the first milestone, earning 4,426 preferred shares, with the remaining 22,086 shares vesting in three equal tranches if additional milestones are achieved. The company states that the full award represents about 4.99% of common stock outstanding on the agreement date, with each milestone tranche equal to about 1.663% of common shares, subject to adjustment if the share count rises.
Oncotelic Therapeutics, Inc. disclosed that it amended an independent contractor agreement with Jefferson Capital Ventures, LLC and a restricted stock award agreement with its CEO, Dr. Vuong Trieu. Both arrangements grant stock awards upon achieving corporate milestones. The amendment lowers the first milestone trigger from a Company market capitalization exceeding $100 million on a single trading day’s close to $45 million on a single trading day’s close.
The company states this change is intended to help it continue building on its progress, including making effective its equity line with Mast Hills, engaging AGP for future financing, and working with Sichenzia, Ross and Ferrell on a potential uplisting of its stock to a nationally recognized exchange. All other terms and conditions of the milestone under Dr. Trieu’s restricted stock award remain unchanged.
Oncotelic Therapeutics, Inc. reported that it amended its independent contractor agreement with Jefferson Capital Ventures, LLC dated August 6, 2025. The change lowers the threshold for the first milestone that triggers restricted stock awards in Oncotelic common stock, reducing the required market capitalization level from $100 million on any single trading day’s close to $45 million on any single trading day’s close. The company states this amendment seeks to enable it to continue building on its progress, including making effective its equity line with Mast Hills, engaging AGP for future financing, and working with Sichenzia, Ross and Ferrell on a potential uplisting to a nationally recognized stock exchange. All other terms and conditions of the milestone remain unchanged.
Oncotelic Therapeutics, Inc. entered into subscription agreements for a third and final tranche of a private financing, issuing 44 units to 22 accredited investors on December 31, 2025. Each unit includes a $25,000 note bearing 12% annual interest and maturing two years after the final closing, along with warrants. The notes are convertible into up to 250,000 shares of Oncotelic common stock at $0.10 per share or 25,000 shares of EdgePoint AI, Inc. common stock at $1.00 per share, both with anti-dilution protection. Each unit also carries 250,000 warrants to buy Oncotelic common stock at $0.12 or 25,000 warrants to buy EdgePoint stock at $1.25 per share.
This tranche completes an offering of up to 500 units conducted by Maker and includes an exchange of certain 2023 notes into the new notes, with related warrants extended by two years. The company also granted investors the ability to convert their EdgePoint shares into Oncotelic shares at the rate of 10 Oncotelic shares for each EdgePoint share. A registration rights agreement covers Oncotelic shares issued in the financing and issuable upon warrant exercise. The securities were issued as unregistered offerings under Regulation D.